Updates

** Shares of drug developer MIRA Pharmaceuticals MIRA.O rise 52.3% to $2.01, nearly one-year high

** Late on Wednesday, company said its experimental oral drug, Mira-55, eased pain and reduced swelling better than injected morphine in a pre-clinical animal study for chronic inflammatory pain

** Mira-55 brought pain levels back to normal and directly reduced inflammation by targeting the CB2 receptor - MIRA

** CB2 receptors are expressed in immune cells and are involved in the regulation of immune responses and inflammation

** Company says morphine only partially reduced inflammation

** Data supports marketing application plans for Mira-55 for chronic inflammatory pain - MIRA

** Including session's move, shares up ~75% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.pandey@thomsonreuters.com))